8-K: Kronos Bio Amends Clinical Trial Protocol for KB-0742, Aims for Increased Patient Exposure

Kronos Bio has modified the dosing schedule for its KB-0742 clinical trial to increase patient exposure to the drug, with updated data expected in mid-2024 and expansion phase results in the first half of 2025.

Summary

• Kronos Bio has amended the protocol for its Phase 1/2 clinical trial of KB-0742, an oral CDK9 inhibitor, in solid tumors.
• The company has observed anti-tumor activity without significant neutropenia at doses between 10 mg and 80 mg using a three-days-on, four-days-off dosing schedule.
• Target engagement, tumor regressions, and an acceptable safety profile were noted at 60 mg with the three-days-on, four-days-off schedule.
• The company has cleared 80 mg with the three-days-on, four-days-off schedule.
• The new protocol will use a four-days-on, three-days-off dosing schedule to increase patient time on the drug at or above a therapeutic threshold.
• Dose escalation will continue with the new schedule at 60 mg and 80 mg before enrolling expansion cohorts at 80 mg.
• Clinical data from existing dose escalation and ongoing expansion cohorts are still expected in mid-2024.
• An update from the new dosing schedule and plans for the dose expansion phase are expected in the third quarter of 2024.
• The expansion cohort is expected to include patients with small cell or non-small cell lung cancer, ovarian cancer, or triple negative breast cancer.
• Topline data from the expansion phase is expected in the first half of 2025.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting progress in the clinical trial and a strategic adjustment to the dosing schedule. However, it also acknowledges risks and uncertainties inherent in drug development, which tempers the overall sentiment.

Positives

• The company has observed anti-tumor activity without grade 3/4 neutropenia at doses ranging from 10 mg to 80 mg.
• Target engagement, tumor regressions, and an acceptable safety profile were observed at 60 mg.
• The company has cleared 80 mg with the previous dosing schedule.
• The change to a four-days-on, three-days-off dosing schedule is intended to increase patient exposure to the drug.
• The company is progressing with dose escalation and expansion cohorts.

Negatives

• The document does not explicitly state any negative results, but the change in dosing schedule could indicate a need to improve efficacy or patient exposure.

Risks

• The company faces risks related to changes in the macroeconomic environment or competitive landscape.
• There are risks associated with progressing clinical trials on the anticipated timelines, including enrollment challenges.
• The company has limited experience in conducting clinical trials.
• Results of preclinical studies and early clinical trials may not be predictive of future results.
• There are risks associated with the sufficiency of the company's cash resources and the need for additional capital.

Future Outlook

The company expects to provide clinical data updates in mid-2024, an update on the new dosing schedule in the third quarter of 2024, and topline data from the expansion phase in the first half of 2025. The company is also planning to expand the trial to include patients with specific types of cancer.

Management Comments

• The company is pursuing a four-days-on, three-days-off dosing schedule to further increase patient time on KB-0742 at or above a therapeutic threshold.

Industry Context

The development of CDK9 inhibitors is an area of active research in oncology, with several companies exploring this target for cancer treatment. Kronos Bio's progress with KB-0742 is part of this broader effort to develop new therapies for solid tumors.

Comparison to Industry Standards

• Many companies are developing CDK9 inhibitors, including but not limited to, Novartis, Pfizer, and Eli Lilly.
• The specific dosing schedule and patient population in this trial will need to be compared to other trials in the space to determine the relative efficacy and safety of KB-0742.
• The reported anti-tumor activity and acceptable safety profile are positive indicators, but further data is needed to assess the drug's potential compared to other treatments.

Stakeholder Impact

• Shareholders will be interested in the progress of the clinical trial and the potential for future revenue.
• Patients with cancer may benefit from the development of new treatment options.
• Employees of Kronos Bio are working on the development of this drug.

Next Steps

• The company will continue dose escalation with the new four-days-on, three-days-off dosing schedule.
• The company will enroll expansion cohorts at the 80 mg dose with the new schedule.
• The company will provide clinical data updates in mid-2024.
• The company will provide an update on the new dosing schedule and expansion phase plans in the third quarter of 2024.
• The company will announce topline data from the expansion phase in the first half of 2025.

Key Dates

Keywords

KB-0742, CDK9 inhibitor, clinical trial, dose escalation, solid tumors, cancer, oncology, dosing schedule, neutropenia, tumor regression